-
Mashup Score: 25Job Advert - 7 day(s) ago
Skip to main content We’ ve put some small files called cookies on your device to help us make improvements to our site. To improve our site we’ d also like to use cookies which will send information to Google Analytics. You can read more about our cookies before you choose. BETA Your feedback will help us to improve this service. The Department has an extremely distinguished record in the provision of clinical services to patients with Leukaemia and Myeloma, including Europe’s first Haematopoietic Stem
Source: beta.jobs.nhs.ukCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma - 2 month(s) ago
To compare disease detection of myeloma using contemporary whole-body (WB) MRI and fluorine 18 ([18] F) fluorodeoxyglucose (FDG) PET/CT protocols and to correlate imaging with laboratory estimates of disease burden, including molecular characteristics.In …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists2Tweet-
Myeloma WB-MRI is more sensitive than FDG-PET/CT https://t.co/w32e48bpTj MRI consistently detected more lesions than FDG-PET/CT, incl vertebra and long bones. Post-treatment scans showed response of all lesions only seen on WB-MRI, strongly suggesting they were true positives https://t.co/HQZT7y8x1U
-
-
Mashup Score: 11Seminar | Modernizing Clinical Trial Design and Analysis to Improve Efficiency & Flexibility - 2 month(s) ago
Ever heard a talk about statistics which is fun? And not just that, a talk that makes sense even if you are not good with numbers? Don’t miss a special from Prof. Frank Harrell who turns complicated into understandable and boring into entertaining! This talk covers several ways to make clinical trials more efficient and to reduce the chance of ending with an equivocal result. Some of the approaches covered are Bayesian sequential designs allowing for study extension if results are promising, not being
Source: mailchi.mpCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 22Top product forecasts for 2024 - 4 month(s) ago
Nature Reviews Drug Discovery – Discover the world’s best science and medicine | Nature.com
Source: www.nature.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 12Blood Cancer Talks - 4 month(s) ago
Listen to Blood Cancer Talks on Spotify. This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk
Source: open.spotify.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 27
Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma: Clinical and Epidemiological: Molecular and Biological Signatures and Predictors of Outcomes Martin F. Kaiser, MD, FRCP, FRCPath 1,2, Rachel Phillip 3 *, Andrew Hall 3 *, Amy Holroyd 4 *, Laura Bevington 4 *, Ruth M de Tute, MSc, PhD, FRCPath 5 *, Laura Clayton 3 *, Sadie Roberts 3 *, Graham Jackson 6 *, Gordon Cook, PhD 7,8 *, Richard S Houlston 4 *, Mark Drayson 9 *, Roger Owen, MD, MRCP, FRCPath 10 *, Guy Pratt 11 *, Sarah R
Source: ash.confex.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma - 5 month(s) ago
To compare disease detection of myeloma using contemporary whole-body (WB) MRI and fluorine 18 ([18] F) fluorodeoxyglucose (FDG) PET/CT protocols and to correlate imaging with laboratory estimates of disease burden, including molecular characteristics.In …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists2Tweet-
Myeloma WB-MRI is more sensitive than FDG-PET/CT https://t.co/w32e48bpTj MRI consistently detected more lesions than FDG-PET/CT, incl vertebra and long bones. Post-treatment scans showed response of all lesions only seen on WB-MRI, strongly suggesting they were true positives https://t.co/HQZT7y8x1U
-
-
Mashup Score: 0
Acknowledging the increasingly important role of whole-body MRI for directing patient care in myeloma, a multidisciplinary, international, and expert panel of radiologists, medical physicists, and hematologists with specific expertise in whole-body MRI in myeloma convened to discuss the technical pe …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists2Tweet-
Yes, early response can be assessed by WB-MRI (MY-RADS) – DW measures cellularity: lesions can be seen ‘melting’, before changing size. Image shows a tiny site of disease post-treatment (arrow in B), and clonal/focal patterns of re-growth (C). From https://t.co/X5duyCuTVP https://t.co/OIoKXiRWqe https://t.co/4dbYilM18X
-
-
Mashup Score: 0Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma - 6 month(s) ago
Publisher’s Note: There is an on this article in this issue.[18] F-Fluorodeoxyglucose (FDG)–positron emission tomography (PET) and diffusion-weighted magnetic resonance imaging with background signal suppression (DWIBS) are 2 powerful functional …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 2Improving real‐world myeloma patient access to whole body MRI through “open‐access” knowledge sharing: The UK experience - 6 month(s) ago
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists2Tweet
For those interested: consider applying for a new permanent myeloma consultant post @royalmarsdenNHS . Join a great team and an expanding myeloma service covering all aspects of myeloma care and clinical research, including T-cell based therapies! https://t.co/DfoeSFI1E3 https://t.co/bytdzVX2SU